Zobrazeno 1 - 10 of 120 pro vyhledávání: '"L Austin Doyle"'
1
Akademický článek
A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.
Autor: Patrick A Ott, Anne Hamilton, Amanda Jones, Naomi Haas, Tsiporah Shore, Sandra Liddell, Paul J Christos, L Austin Doyle, Michael Millward, Franco M Muggia, Anna C Pavlick
Publikováno v: PLoS ONE, Vol 5, Iss 1, p e8714 (2010)
Ixabepilone (BMS-247550), an epothilone B analog, is a microtubule stabilizing agent which has shown activity in several different tumor types and preclinical models in melanoma. In an open label, one-arm, multi-center phase II trial the efficacy and
Externí odkaz: https://doaj.org/article/bcaa7301c3184c05ad9a4660ad8a3bc0
Zobrazit plný text záznamu
2
Akademický článek
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Autor: Yan Xing, Nancy U. Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-MacGregor, Vicente Valero, Sarina A. Piha-Paul, David Hong, Kim-Anh Do, Emily Tarco, Dianna Riall, Agda Karina Eterovic, Gerburg M. Wulf, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Eric Winer, Gabriel N. Hortobagyi, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam
Publikováno v: Breast Cancer Research, Vol 21, Iss 1, Pp 1-12 (2019)
Abstract Background The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer who had tumors with
Externí odkaz: https://doaj.org/article/3eaaeb80b88d4c81acd24e596bc7212d
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje